This site is intended for healthcare professionals

European Commission approves Kinpeygo for adults with primary IgA nephropathy.- Calliditas Therapeutics AB + Stada Arzneimittel AG.

Read time: 1 mins
Published:25th Jul 2022

Calliditas Therapeutics AB announced that the European Commission (EC) has granted conditional marketing authorization for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) greater than 1.5 g/gram.

Kinpeygo is an orphan medicinal product and the first and only approved treatment for IgAN, a rare, progressive autoimmune disease of the kidney with a high unmet need, with more than 50% of patients potentially progressing to end-stage renal disease (ESRD).

Kinpeygo will be marketed in the European Economic Area (EEA) exclusively by STADA Arzneimittel AG.

Condition: IgA Nephropathy/Bergers disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.